Cholestasis and cholestatic syndromes

Current Opinion in Gastroenterology

Volumn 21, Issue 3, 2005, Pages 270-274

  Pratt, Daniel S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biliary atresia; Chotestasis; Intrahepatic cholestasis of pregnancy; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

BILE ACID; COLCHICINE; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; S ADENOSYLMETHIONINE; TAMOXIFEN; TRANSMEMBRANE CONDUCTANCE REGULATOR; URSODEOXYCHOLIC ACID;

BILE DUCT ATRESIA; BILIARY TRACT DISEASE; CHOLESTASIS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER TRANSPLANTATION; PATHOGENESIS; PREGNANCY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVIEW; SYNDROME DELINEATION;

BILE ACIDS AND SALTS; BILIARY ATRESIA; CHOLANGITIS, SCLEROSING; CHOLESTASIS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SYNDROME;

EID: 17844381585     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000159819.01403.39     Document Type: Review

References (31)

1. Anwer MS. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology 2004; 39:581-590. An excellent review of the regulation of bile acid transport.
2. Denk GU, Soroka CJ, Takeyamam Y, et al. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol 2004; 40:585-591. Mrp4 upregulation in cholestasis provides a mechanism to eliminate excess bile salts.
3. Assem M, Schuetz EG, Leggas M, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004; 279:22250-22257. Sult2a also appears to play a role in the excretion of toxic bile acids during cholestasis.
4. Shivakumar P, Campbell KM, Sabla GE, et al. Obstruction of the extrahepatic bile ducts by lymphocytes is regulated by IFN-γ in experimental biliary atresia. J Clin Invest 2004; 114:322-329. Suggests a possible central role for IFN-γ in the pathogenesis of biliary atresia.
5. Chen F, Ananthanarayanan M, Emre S, et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 2004; 126:756-764. Aberrant regulation of intestinal and hepatic bile acid transport, mediated by decreased FXR expression, may contribute to the pathophysiology of PFIC1.
6. Klomp LW, Vargas JC, van Mil SWC, et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 2004; 40:27-38.
7. Gissen P, Johnson CA, Morgan NV, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004; 36:400-404.
8. Lumbroso S, Paris F, Sultan C. Activating Gsa mutations: analysis of 113 patients with signs of McCune-Albright Syndrome - a European collaborative study. J Clin Endocrinol Metab 2004; 89:2107-2113.
9. Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy. relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40:467-474. Study suggesting it may be possible to identify patients with ICP at highest risk for fetal complications.
10. Roncaglia N, Locatelli A, Arreghini A, et al. A randomized controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG 2004; 11:17-21.
11. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins:genetics, epigenetics, and environment. Gastroenterology 2004; 127:485-492.
12. Xu L, Sakalian M, Shen Z. Cloning the human betaretrovirus praviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39:151-156. Suggests a role for a viral infection in triggering PBC.
13. Selmi C, Ross SR, Ansari AA. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127:493-501. A study refuting an association between human betaretrovirus and PBC.
14. Bogdanos DP, Baum H, Grasso A, et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004; 40:31-39.
15. Plamer J, Robe AJ, Burt AD, et al. Covalent modification as a mechanism for the breakdown of immune tolerance to pyruvate dehydrogenase complex in the mouse. Hepatology 2004; 39:1583-1592. This study showed how xenobiotics could produce altered self-antigens and loss of immune tolerance.
16. Matsumura S, Van de Water J, Leung P. Caspase induction by IgA antimitochondrial antibody. IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology 2004; 39:1415-1422. First study to suggest a possible pathogenic role for AMA.
17. Invernizzi P, Miozzo M, Battezzati I, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004; 363:533-534.
18. Reddy A, Prince M, James OF, et al. Tamoxifen: a novel treatment for primary biliary cirrhosis. Liver Int 2004; 24:194-197.
19. Invernizzi P, Alvaro D, Crosignani A, et al. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39:1175-1176.
20. Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol 2004:264-268.
21. Levy C, Angulo P. Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis. Am J Gastroenterol 2004; 99:269-270.
22. Kaplan MM, Cheng S, Price LL, Bonis PAL. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004; 39:915-923. Results of a long-term study comparing colchicine to methotrexate in PBC.
23. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126:1929-1930.
24. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127:261-274.
25. Yang X, Cullen SN, Li JH, et al. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004; 40:375-379.
26. Blanco PG, Zaman MM, Junaidi O, et al. Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 2004; 287:G491-G496.
27. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40:693-698. Shows that biliary enrichment with UDCA plateaus at a dose of 22-25 mg/kg and that this may represent the optimal dose in patients with PSC.
28. Bjomsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:502-508.
29. Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99:1105-1110.
30. Bellmann R, Graziadei IW, Feistritzer C, et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10:107-114.
31. Bellmann R, Feistritzer C, Zoller H, et al. Treatment of intractable pruritus in drug induced cholestasis with albumin dialysis: a report of two cases. ASAIO J 2004; 50:387-391.